Deal Flow Alert: Orbital Therapeutics Hires Adam Raff
Orbital Therapeutics names Adam Raff as SVP, Clinical Development. This is your next touch. Pitch CTMS to accelerate IND studies. Offer regulatory intelligence to streamline submissions and drive your pipeline.
Published on
Do not index
Do not index
🚀 Battle Card: Orbital Therapeutics
Quick trigger:
As an Orbital Therapeutics sales trigger, this is your cue to engage with their clinical ops revamp.
👤 Decision Maker in the News
- Adam Raff, M.D., Ph.D., Senior Vice President, Clinical Development · 🔗 LinkedIn
💡 Why It Matters
- New SVP to steer clinical & regulatory ops for OTX-201’s IND-enabling studies → Source
- This Orbital Therapeutics sales trigger signals heavy investment in clinical and regulatory tech
🎯 Core Pain Point
- Accelerate IND-enabling study timelines
- Ensure regulatory alignment across global markets
💰 What to Pitch
- Primary: Clinical trial management platform → Shorter protocol development to accelerate trial start
- Expansion: Regulatory intelligence solution → Comprehensive guidance to streamline submissions
🗺️ Quick Context
- HQ: Cambridge, MA
- Employees: ≈ 120
- Rev: ≈ $15 M
- Website: orbitaltx.com
🤼 Competitive Intel
*Which other vendors you’ll probably face to win Orbital Therapeutics’s business.*
- Veeva — Clinical Operations / eTMF
- Unique edge: Industry-standard vault for trial docs
- Evaluated by SVP Clinical for platform scalability
- Medidata — eClinical / Trial Analytics
- Unique edge: Advanced analytics & patient engagement
- Evaluated by Clinical Ops for real-time data insights
- Oracle Health Sciences — Clinical Trial Management
- Unique edge: Integrated CTMS & EDC
- Evaluated by Regulatory leads for global compliance
- Parexel — Clinical Research Org.
- Unique edge: End-to-end CRO services
- Evaluated by Clinical Dev for strategic outsourcing
- Covance — CRO / Lab Services
- Unique edge: Extensive bioanalytical capabilities
- Evaluated by Ops for sample logistics support
✅ Do-Now Checklist
Connect with Adam Raff, M.D., Ph.D. on LinkedIn
Send first touch email + DM with the Copy-My-Prompt block
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
Don’t miss an Orbital Therapeutics sales trigger—get intel like this daily.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑TrialOps❑
OFFER_BRIEF = ❑unified CTMS to accelerate IND-enabling studies❑
PROOF_METRIC = ❑30% faster study startup❑
CTA_STYLE = ❑quick_call❑
TONE = ❑punchy❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Adam
COMPANY = Orbital Therapeutics
DEPT = Clinical Development
SIZE = ≈15
BOTTLENECK = IND-enabling study delays
EVENT = Appointment of Adam Raff as SVP Clinical Development
DETAIL = overseeing OTX-201 IND-enabling studies
PAIN = need to accelerate IND-enabling study timelines
SRC = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250904884085&div=41152219
SIM_CO = Montai Therapeutics
WIN_METRIC = 30% faster study startup
NEXT_SIZE = ≈30
EMP_EST = ≈120
REV_EST = ≈15M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: ≈15-person Clinical Development
Adam—noticed your Clinical Development team is ≈15.
That’s when IND-enabling study delays slows growth.
We helped Montai Therapeutics fix this with unified CTMS to accelerate IND-enabling studies.
Result: 30% faster study startup.
Quick call?
PS—next bottleneck hits ≈30.
DM ≤45 words, TONE:
Saw your post about overseeing OTX-201 IND-enabling studies — need to accelerate IND-enabling study timelines.
Unified CTMS to accelerate IND-enabling studies. 30% faster study startup.
Quick chat?